Exclusion Criteria |
---|
Administration of any investigational drug in the period 0 to 3 months before entry to the study (0 to 4 months if the previous investigational drug was a new chemical entity) |
A need for any medication (including OTC drugs, e.g., aspirin) during the period 0 to 7 days before entry to the study |
Existence of any surgical or medical condition which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug |
Presence or history of allergy requiring treatment |
Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study |
Serious adverse reaction or hypersensitivity to any drug, especially heparin |
History of easy bruising |
Personal or family history or coagulation or bleeding disorders, cerebral hemorrhage, or reasonable suspicion or vascular malformations, including aneurysms |
History of important bleeding, e.g., hematemesis or melena, severe or recurrent epistaxis or hemoptysis |
Known heparin resistance |
Consumption of aspirin in any form, or of other non-steroidal anti-inflammatory drugs within the 3 weeks prior to the final eligibility check |
Rectal bleeding, including that presumed from hemorrhoids within 3 months prior to screening |
Surgery or significant trauma within the 3 months prior to screening |
Significant epigastric pain or indigestion either chronically or within 4 weeks prior to screening |
Platelet aggregation response of 40% to 10 μmol/L ADP and 2 μg/mL collagen |
Abnormal platelet aggregation response to arachidonic acid |
Inability to communicate or co-operate with the investigator because of a language problem, poor mental development or impaired cerebral function |
Smokers |
Objection by the subject's general practitioner to his/her patient's participation in the study |